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The sudden death of Dr. Judah Folkman 
was tragic, not the least because he 
had so much left to do. Director of the 
Vascular Biology Program and former 
Surgeon-in-Chief at Children’s Hos-
pital Boston, he died while en route to 
address a scientific meeting in Vancou-
ver. His laptop was open on his lap; he 
had an exhaustive list of investigations 
underway, all aimed at expanding the 
diagnostic and therapeutic possibilities 
of the field he had founded—angiogen-
esis research.
The story of how Judah persevered 
in the face of skepticism to prove that 
tumors require a blood supply to grow 
is legendary. On the long road to estab-
lishing angiogenesis as a major field, 
he always asked the next question, 
suggested the next experiment, made 
the unexpected connections of which 
discovery is born. He brought compas-
sion and wisdom to his roles of healer, 
scientist, teacher, and mentor. Judah 
had an extraordinary dedication to his 
patients day and night.
Moses Judah Folkman was born in 
Cleveland, Ohio, and grew up in the science as his life’s love, and he was 
drafted for a two-year stint in the Navy. 
While posted at the National Naval 
Medical Center in Bethesda, Maryland, 
Judah conducted experiments that 
stimulated the ideas that would mature 
into his angiogenesis hypothesis.
The scientific community first learned 
of Judah’s angiogenesis theory in 1971, 
when he published a seminal paper in 
the New England Journal of Medicine. 
In it, he proposed that tumors could not 
grow beyond a certain size without a 
dedicated blood supply. He postulated 
that they secreted a protein to stimulate 
the ingrowth of capillaries, and that this 
process, angiogenesis, transformed a 
tumor composed of mutated but harm-
less cells into a potentially lethal neo-
plasm. Since physiological processes 
most often have checks and balances, 
he further proposed that naturally occur-
ring substances that inhibited angiogen-
esis kept some tumors dormant despite 
their malignant potential.
The decade that followed was a chal-
lenging period spent identifying the 
molecular basis of tumor angiogenesis. Cancer CelToward this end, Judah developed the 
assays and tools to study angiogenesis 
in vivo and in vitro. These assays remain 
in use today. They include long-term 
culture of capillary endothelial cells, 
the chick chorioallantoic membrane 
and corneal pocket bioassays, and the 
sustained-release polymers required 
to deliver angiogenic regulators to be 
tested.
In the early 1980s, the lab purified 
the first angiogenic stimulator, basic 
fibroblast growth factor (bFGF), which 
ushered in an era of discovery, valida-
tion, and refinement that established 
angiogenesis as the defining process in 
a tumor’s ability to grow and metasta-
size. In the decades since, Judah’s lab 
and others have identified more than 30 
endogenous angiogenesis inhibitors, 
including angiostatin and endostatin, 
and over a dozen stimulators, and they 
have begun mapping multiple pathways 
through which pathological angiogen-
esis occurs. Drugs based on these dis-
coveries are now benefiting more than 
1.2 million people worldwide. Ten are 
approved in the US and other countries Midwest. He knew by age 10 that 
medicine was his calling. The 
book Dr. Folkman’s War, by Rob-
ert Cooke, vividly recounts his 
formative experiences, from visit-
ing hospitalized congregants with 
his rabbi father to spending hours 
as a teenager practicing surgical 
knots and suturing the family’s 
dish towels together, a foreshad-
owing of the single-minded focus 
and perseverance that would 
define his career.
Judah entered Harvard Medi-
cal School at 19, served his 
residency at the Massachusetts 
General Hospital, and, at 34, was 
appointed Surgeon-in-Chief at 
Children’s, becoming one of the 
youngest full professors in Har-
vard Medical School history. Two 
pivotal events during Judah’s resi-
dency years set his future course: 
he married Paula Prial, with whom 
he raised the family that rivaled l 13, Ffor cancer and the wet form of 
age-related macular degeneration 
(ARMD), which is also angiogen-
esis dependent; another 40-plus 
are in clinical trials. The ARMD 
drugs are the first ever to reverse 
blindness.
Judah was gratified but not 
satisfied with these advances. As 
always, his vision was bigger. In 
1989, he proposed the concept 
of the “angiogenic switch,” the 
point in a tumor’s development 
when the balance of stimulators 
and inhibitors is altered in favor 
of angiogenesis stimulation, trig-
gering the transition to the angio-
genic phenotype. He theorized 
that blocking the switch would 
keep cancer from developing. The 
key would be to identify biomark-
ers of the switch, then “treat the 
biomarker” with nontoxic angio-
genesis inhibitors, akin to using 
statins in response to high choles-ebruary 2008 ©2008 Elsevier Inc. 81
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trials to evaluate the efficacy of 
biomarkers in detecting recurrent 
cancer before the tumors could 
be imaged or palpated, a first 
step toward his vision of “cancer 
without disease.”
His vision for angiogenic thera-
pies did not stop there, however. 
He viewed angiogenesis as an 
organizing principle of biology 
and pathological angiogenesis 
as a common factor in many dis-
parate diseases. He pointed out 
that angiogenesis is necessary to 
support the growth of any mass—
be it an arthrosclerotic plaque, 
adipose tissue, or a malignancy, 
and that it characterizes condi-
tions as different as retinopathies 
and endometriosis. This shared 
characteristic led Judah to pro-
pose that angiogenesis-based 
biomarkers could be used to 
monitor the progression or regression 
of a number of these diseases. Further, 
drugs developed for one angiogenesis-
dependent disorder could potentially 
treat another. This had already hap-
pened with Avastin, the cancer drug 
some ophthalmologists used to suc-
cessfully treat wet ARMD before the 
more targeted eye drugs Lucentis and 
Macugen received approval. Judah 
envisioned a time when a single, broad-
spectrum angiogenesis inhibitor or a 82 Cancer Cell 13, February 2008 ©2008 Elcombination of antiangiogenic drugs 
would be used to treat a wide range of 
conditions.
Judah Folkman authored some 400 
peer-reviewed papers and more than 100 
book chapters and monographs. He had 
been elected to the National Academy of 
Sciences, the American Academy of Arts 
and Sciences, the American Philosophi-
cal Society, the Institute of Medicine, 
and the President’s Cancer Advisory 
Board. The research lab he founded with sevier Inc.a single assistant when he came 
to Children’s Hospital Boston in 
1967 had, by the time of his death, 
grown into a 100-scientist-strong 
Vascular Biology Program. More 
than 1000 labs around the world 
are now pursuing angiogenesis 
research, yielding thousands of 
angiogenesis-related publications 
each year.
That the challenge Judah Folk-
man faced in 1971 had been met 
was nowhere more apparent 
than in the awards and honor-
ary degrees crowding every inch 
of the walls of one of the Vascu-
lar Biology Program’s conference 
rooms. But the display in a second 
conference room was even more 
meaningful to him. There, the walls 
exhibit journal covers reflecting 
the achievements of all 13 of the 
Vascular Biology Program’s labs, 
many of which are now run by sci-
entists who began their careers as Folk-
man post-docs. Judah was intensely 
proud of his scientific progeny.
Judah Folkman’s fiercely original and 
courageous intelligence, his gift for 
focusing on big, important questions 
that could make a difference in people’s 
lives, and his delight in discovery inspired 
hundreds of scientists, clinicians, and 
patients all over the world. We are hon-
ored and grateful to have been witness 
to his genius and his selflessness.
Michael Klagsbrun1,* and Marsha A. 
Moses1,*
1Vascular Biology Program, Children’s 
Hospital Boston, Department of Surgery, 
Children’s Hospital Boston and Harvard 
Medical School, 300 Longwood Avenue, 
Boston, MA 02115, USA
*Correspondence: michael.klagsbrun 
@childrens.harvard.edu (M.K.); marsha.
moses@childrens.harvard.edu (M.A.M.)
DOI 10.1016/j.ccr.2008.01.020
